Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA55 Injection in Mild/Moderate COVID-19
NCT06042764Phase 2Recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SA55 in coronavirus disease 2019 (COVID-19), sponsored by Sinovac Life Sciences. Started Aug 2023; status: recruiting.
02
Drugs
SA55
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06042764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042764.